Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Mayo Clin Proc. 2021 Nov 9;96(12):3021–3029. doi: 10.1016/j.mayocp.2021.06.025

Table 5.

Serum Glucose and Other Glycemic Indices After One Year of TKI Therapy, Excluding Prior TKI Therapy

Dasatinib Imatinib Difference * P-value
Number 8 26
Serum Glucose −33.6 ± 30.1 12.3 ± 43.6 −45.9 0.007
Total daily insulin (Units) −33 ± 30.0 5.3 ± 19.2 −38.3 0.30
Other antihyperglycemic medications 0 ± 0.0 0.04 ± 0.45 −0.04 0.66
Weight (kg) −2.8 ± 4.71 3.2 ± 9.30 60 0.02
Body mass (%) −2.7 ± 3.8 3.6 ± 8.9 63 0.02
*

P-values obtained using a 2-tailed two-sample t-test assuming unequal variances for continuous variables, or Fisher’s exact test for categorical variables